Literature DB >> 9215396

Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX.

S C Chang1, G A Buonaccorsi, A J MacRobert, S G Bown.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is an experimental approach for treating prostate cancer localized to the gland that does not involve surgery or irradiation. Second-generation photosensitizers 5-aminolevulinic acid (ALA) and aluminum disulfonated phthalocyanine (AlS2Pc) were studied in the normal canine prostate.
METHODS: Tissue biodistribution of photosensitizers on serial biopsies was examined using fluorescence microscopy. Photodynamic therapy was done by delivering red light interstitially at 100 mW through fibers placed under transrectal ultrasound guidance.
RESULTS: Peak levels of AlS2Pc appeared at 5-24 hr and at 3 hr for ALA. Macroscopic PDT lesions were up to 12 mm in diameter using AlS2Pc, but only 1-2 mm with ALA. Light at 300 mW caused thermal lesions. At 28 days, damaged glands remained atrophic, but the interlobular supporting stroma was well-preserved. Urethral lesions healed by 28 days without functional impairment.
CONCLUSIONS: Although the results with ALA were disappointing, PDT using AlS2Pc looks like a promising modality for treatment of localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215396     DOI: 10.1002/(sici)1097-0045(19970701)32:2<89::aid-pros3>3.0.co;2-a

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.

Authors:  Zheng Huang; Qun Chen; Nadira Trncic; Susan M LaRue; Pierre-Hervé Brun; Brian C Wilson; Howard Shapiro; Fred W Hetzel
Journal:  Radiat Res       Date:  2004-06       Impact factor: 2.841

Review 2.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

3.  Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model.

Authors:  Kenneth C Dole; Qun Chen; Fred W Hetzel; Lawrence R Whalen; Dominique Blanc; Zhen Huang
Journal:  Photomed Laser Surg       Date:  2005-04       Impact factor: 2.796

4.  The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues--in vivo study in a canine model.

Authors:  Zheng Huang; Qun Chen; Kenneth C Dole; Al B Barqawi; Yang K Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Photochem Photobiol Sci       Date:  2007-08-22       Impact factor: 3.982

Review 5.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 6.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

7.  Interstitial PDT using diffuser fiber-investigation in phantom and in vivo models.

Authors:  Mirian D Stringasci; Thereza C Fortunato; Lilian T Moriyama; José Dirceu Vollet Filho; Vanderlei S Bagnato; Cristina Kurachi
Journal:  Lasers Med Sci       Date:  2017-05-05       Impact factor: 3.161

8.  Prostate PDT dosimetry.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Photodiagnosis Photodyn Ther       Date:  2006-10-19       Impact factor: 3.631

9.  Optimization of light sources for prostate photodynamic therapy.

Authors:  Martin D Altschuler; Timothy C Zhu; Jun Li; Stephen M Hahn
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2005-04-22

10.  High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model.

Authors:  Baowei Fei; Hesheng Wang; Joseph D Meyers; Denise K Feyes; Nancy L Oleinick; Jeffrey L Duerk
Journal:  Lasers Surg Med       Date:  2007-10       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.